Inceptionr LLC Takes Position in Pfizer Inc. $PFE

Inceptionr LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 19,784 shares of the biopharmaceutical company’s stock, valued at approximately $504,000.

A number of other large investors have also added to or reduced their stakes in PFE. Grey Fox Wealth Advisors LLC bought a new position in shares of Pfizer during the 3rd quarter valued at approximately $29,000. Howard Hughes Medical Institute bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $30,000. Darwin Wealth Management LLC purchased a new position in Pfizer in the second quarter valued at approximately $32,000. Evelyn Partners Asset Management Ltd bought a new position in Pfizer during the second quarter valued at $33,000. Finally, True Wealth Design LLC increased its position in Pfizer by 302.5% in the third quarter. True Wealth Design LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 974 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase‑2 readout for tilrekimig (PF‑07275315) — the study met its primary endpoint (EASI‑75 at Week 16) and Pfizer plans late‑stage testing, which materially strengthens the company’s dermatology pipeline and future growth prospects. Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate-to-Severe Atopic Dermatitis Pfizer’s eczema drug meets main goal in mid-stage trial
• Neutral Sentiment: FDA approved leucovorin for a rare genetic condition but not for autism — important regulatory news for the sector but not directly tied to Pfizer’s marketed products or near‑term revenue. FDA Approves Leucovorin—But Not For Autism
• Neutral Sentiment: Patent activity around tafamidis (a competing transthyretin amyloidosis drug) and related market moves lifted other small caps — the BridgeBio story signals shifting patent dynamics that could influence competitive positioning over time but the impact on Pfizer is uncertain. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
• Neutral Sentiment: BioNTech cofounders stepping down rattled biotech sentiment broadly; this is sector noise that can increase volatility but does not directly affect Pfizer’s fundamentals. BioNTech Cofounders To Step Down. Stock Crumbles.
• Negative Sentiment: Investor concern over Pfizer’s payout ratio (reported >100%) and a quarterly loss raised the specter of dividend pressure — this remains a key negative risk that can cap upside and prompt selling. Pfizer’s Payout Ratio Is Still Over 100%. Is a Dividend Cut Inevitable?
• Negative Sentiment: Despite the positive eczema data, some reports noted shares dipped earlier — signaling profit‑taking and investor skepticism that new pipeline data will immediately translate to material revenue. That caution can mute sustained rallies. Pfizer shares dip despite positive trial results for skin condition drug

Pfizer Stock Up 1.2%

PFE stock opened at $27.12 on Wednesday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The stock has a market cap of $154.22 billion, a price-to-earnings ratio of 19.94 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company’s 50 day moving average is $26.38 and its 200 day moving average is $25.49.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.63 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.3%. The ex-dividend date of this dividend was Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Barclays assumed coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price target on the stock. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Finally, Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research note on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.